Robert Garnick joins Peregrine
This article was originally published in SRA
Executive Summary
Peregrine Pharmaceuticals in the US has appointed Robert Garnick head of regulatory affairs. Dr Garnick will be responsible for overseeing Peregrine's interactions with the US Food and Drug Administration and global regulatory agencies; he will also lead the development of regulatory strategies for advancing the company's monoclonal antibody-based treatments for cancer and infectious diseases.